hsa-mir-4530: Hsa-mir-4530 is one of the miRNAs that have been found to be related to EV71 infection for the first time [PMC4416288]. It is one of the eight miRNAs that were significantly up-regulated in response to EV71 infection [PMC4416288]. Additionally, hsa-mir-4530 has been identified as one of the differentially expressed miRNAs between leiomyoma and myometrium, with its expression being down-regulated in leiomyoma [PMC9154092]. Hsa-mir-4530 has also been reported to be involved in regulating inflammatory response [PMC9039132]. However, there is no evidence in the provided context to support the claim that hsa-mir-4530 regulates cancer-related target genes [PMC8240180]. Overall, hsa-mir-4530 has been implicated in various biological processes and diseases such as EV71 infection, leiomyoma development, and inflammatory response regulation [PMC4416288][PMC9154092][PMC9039132].

MIR4530: MIR4530 is a microRNA that has been studied in the context of pancreatic cancer and normal-like subtypes. In a study assessing the expression levels and diagnostic performance of miR-125a-3p, MIR4530, and miR-92a-2-5p in plasma samples from pancreatic cancer patients and noncancerous controls, MIR4530 was included as part of a panel [PMC9569215]. The study found that MIR4530, along with miR-125a-3p and miR-92a-2-5p, could potentially be used as diagnostic markers for pancreatic cancer. Additionally, it was discovered that MIR4530 is regulated by H3K4me3 at the promoter level and may have a protective role in normal-like subtypes [PMC8261273]. In normal-like cell line MCF10A, MIR4530 was found to play a role in suppressing cell proliferation, promoting angiogenesis, and inducing apoptosis by targeting the gene VASH1 [PMC8261273]. However, in another study focusing on patients with amyotrophic lateral sclerosis (ALS), including both familial (fALS) and sporadic (sALS) cases, it was found that MIR4530 was not differentially expressed [PMC6416171]. In fALS patients specifically, four microRNAs including MIR4530 were downregulated [PMC6416171]. However, in sALS patients as well as sporadic cases of ALS overall, the expression levels of these microRNAs were not significantly altered except for downregulated miR1234-3p and miR1825 [PMC9100918].